CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.654
EU - Europa 5.271
AS - Asia 4.960
SA - Sud America 778
AF - Africa 79
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 17.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.570
CN - Cina 1.907
SG - Singapore 1.735
GB - Regno Unito 1.448
BR - Brasile 687
RU - Federazione Russa 673
IT - Italia 645
HK - Hong Kong 624
DE - Germania 513
SE - Svezia 475
FR - Francia 443
IE - Irlanda 410
FI - Finlandia 287
VN - Vietnam 200
KR - Corea 130
UA - Ucraina 98
IN - India 76
NL - Olanda 68
ID - Indonesia 49
CA - Canada 40
BE - Belgio 39
JP - Giappone 39
AR - Argentina 35
TR - Turchia 35
AT - Austria 32
BD - Bangladesh 30
AU - Australia 29
PL - Polonia 28
MX - Messico 27
ES - Italia 23
IR - Iran 22
TG - Togo 22
IQ - Iraq 17
RO - Romania 14
MA - Marocco 13
AZ - Azerbaigian 11
CO - Colombia 11
EC - Ecuador 11
VE - Venezuela 11
ZA - Sudafrica 11
CL - Cile 10
CZ - Repubblica Ceca 10
GR - Grecia 10
UZ - Uzbekistan 10
CH - Svizzera 9
NP - Nepal 9
DK - Danimarca 7
NO - Norvegia 7
CG - Congo 6
KZ - Kazakistan 6
LT - Lituania 6
PE - Perù 6
PK - Pakistan 6
DZ - Algeria 5
KG - Kirghizistan 5
TN - Tunisia 5
TW - Taiwan 5
EU - Europa 4
JM - Giamaica 4
JO - Giordania 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AM - Armenia 3
CR - Costa Rica 3
EG - Egitto 3
HU - Ungheria 3
IL - Israele 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
MY - Malesia 3
PH - Filippine 3
PY - Paraguay 3
SA - Arabia Saudita 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
BY - Bielorussia 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KH - Cambogia 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UG - Uganda 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
Totale 17.764
Salva come PNG Salva come JPEG
Città #
Southend 1.303
Chandler 968
Dallas 923
Singapore 770
Hong Kong 619
Woodbridge 505
Beijing 429
Dublin 408
Ann Arbor 329
Ashburn 318
Jacksonville 267
Houston 256
Wilmington 194
Verona 188
Lawrence 172
Princeton 172
New York 140
The Dalles 135
Jinan 133
Shenyang 122
Nanjing 121
Los Angeles 112
Munich 97
Redmond 88
Sindelfingen 78
Columbus 77
Hebei 76
Buffalo 75
Helsinki 73
Redondo Beach 73
Tianjin 58
São Paulo 53
Zhengzhou 53
Changsha 46
Falls Church 46
Nanchang 46
Santa Clara 46
Ho Chi Minh City 45
Taizhou 45
Fuzhou 44
Ningbo 44
Milan 43
Redwood City 43
Bologna 42
Dong Ket 40
Brussels 39
Guangzhou 38
Haikou 37
Hangzhou 37
Jakarta 37
Nuremberg 36
Seoul 36
Turku 36
Tokyo 34
Seattle 33
Chicago 30
Norwalk 30
San Francisco 30
Hanoi 28
Kent 27
Moscow 27
Jiaxing 26
Taiyuan 25
Council Bluffs 22
Falkenstein 22
Lomé 22
Rio de Janeiro 22
Groningen 21
Rome 21
Belo Horizonte 19
Warsaw 19
Frankfurt am Main 18
Boardman 17
Boston 16
Dearborn 16
Provo 16
Düsseldorf 15
Shanghai 15
Vienna 15
Brasília 14
Lanzhou 14
Amsterdam 13
San Giovanni Lupatoto 13
Chengdu 12
Lancaster 12
Perth 12
Washington 12
Atlanta 11
Baku 11
Toronto 11
Kochi 10
London 10
Mexico City 10
Tashkent 10
Brescia 9
Chennai 9
Dhaka 9
Lappeenranta 9
Naples 9
Porto Alegre 9
Totale 11.026
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 263
A study of the crosstalk between CD30 and CXCR4 185
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 178
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 177
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 172
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 170
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 168
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 160
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 160
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 157
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 155
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 152
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 151
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 151
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 148
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 148
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 147
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 146
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 145
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 145
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 143
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 142
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 141
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 141
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 140
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 140
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 138
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 137
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 137
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 136
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 135
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 129
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 126
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 126
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 124
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 123
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 123
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 122
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 121
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 121
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 120
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 118
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 118
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 118
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 117
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 117
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 117
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 116
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 116
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 115
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 115
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 115
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 114
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 113
Bone Disease in Mastocytosis 113
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 112
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 110
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 110
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 110
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 109
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 109
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 108
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 107
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 106
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 106
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 106
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 104
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 104
In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants 102
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 102
Skeletal implications of isolated bone marrow mastocytosis (reply): Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis (reply) 101
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 101
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 101
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 100
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 99
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 99
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 99
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 98
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 98
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 98
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 97
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 97
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 97
The Plant-Derived Agent {alpha}-Bisabolol Induces Apoptosis of Leukemic Blasts Ex Vivo. 96
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 96
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 96
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 95
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 94
Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). 93
How patients perceive a switch from imatinib to nilotinib: results of a patient-centered analysis 92
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 92
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 91
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 91
TCL1A expression in marginal zone lymphoma: a clinico-pathological evaluation in paired spleen and bone marrow samples 90
Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes 89
Mast Cell Disorders In Drug Hypersensitivity 89
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 89
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 89
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 88
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 88
Totale 12.113
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.200
article - articoli 48.958
book - libri 0
conference - conferenze 23.864
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 378
Totale 146.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021830 0 0 0 134 218 108 22 22 50 20 162 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/20262.882 881 747 903 351 0 0 0 0 0 0 0 0
Totale 18.081